About: http://data.cimple.eu/news-article/0e28fd1817f9a094dbd6b3f6e3159a1d321c1e9b0575a72b9461e13f

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/0e28fd1817f9a094dbd6b3f6e3159a1d321c1e9b0575a72b9461e13f Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Clinical trials for a vaccine against the new virus sweeping China could be carried out in the summer, the head of an anti-epidemic coalition said on Thursday. "We can announce that we have three partnerships to develop vaccines against the novel coronavirus," Richard Hatchett, chief executive of the Coalition for Epidemic Preparedness Innovations (CEPI) said in Davos. "Our goal is to have these vaccines developed very rapidly and to move very rapidly to begin clinical trials, perhaps as early as the summer," Hatchett said during the annual World Economic Forum in the Swiss ski resort town. There is no vaccine or antiviral treatment against the novel coronavirus detected in China, which has killed 18 people so far and has now spread internationally. Hatchett said the three partnerships were with Inovio Pharmaceuticals, a US-based company, the University of Queensland in Australia and Moderna, another US biotech firm. Moderna is working with the US National Institute of Allergy and Infectious Diseases, a US government agency. Shares in Inovio jumped 6.68 percent on the New York Stock Exchange on Thursday, while Moderna stock was up 1.37 percent and by a total of 6.5 percent over two sessions. Shares in other biotech companies also rose in expectation of growing interest in a vaccine against the virus. Stock in Novavax, which has previously carried out research on Severe Acute Respiratory Syndrome (SARS), jumped 11.42 percent, while NanoViricides, which is conducting research into Ebola, rose 36.91 percent. Hatchett said that even if the virus had disappeared by the time a vaccine is developed, having one would still be "very advantageous". "If the virus doesn't disappear and it spreads globally, we will be glad that we made these investments today," he added. Staphane Bancel, chief executive of Moderna, told AFP that his company planned to develop the vaccine at its plant in Boston with financing from CEPI. Bancel also said he planned clinical trials by the summer, adding "normally to develop traditional vaccines the same process would take two or three years". jug/dt/pvh
schema:headline	Three groups working on vaccines for China virus
schema:mentions	Novavax Ski resort Severe acute respiratory syndrome Advantageous Jug New York Stock Exchange Agence France-Presse Antiviral drug Queensland Allergy Boston Ebola virus disease Switzerland World Economic Forum Australia Vaccine China Severe acute respiratory syndrome coronavirus 2 Inovio Pharmaceuticals PVH (company)
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-01-23 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	71 (xsd:integer)

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software